Novoron Bioscience Welcomes Dr. David Weiner to the Board of Directors
Novoron Bioscience is excited to announce that Dr. David Weiner is the newest member of the Board of Directors. Dr. Weiner has over 20 years of experience in the discovery and clinical development of novel therapeutics for neurological disease. David started his career in biotech at ACADIA Pharmaceuticals, formerly led EMD Serono’s global early clinical development activities in neurology, has served as CMO and Interim CEO for Proteostasis Therapeutics Inc. (Yumanity), and most recently as CMO at Lumos Pharma. David received his MD from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, and was a Howard Hughes Medical Institute Research Scholar at the National Institute of Health in Bethesda.
Speaking on the appointment, Novoron Bioscience CEO, Dr. Travis Stiles, said “We are thrilled to welcome Dr. David Weiner to Novoron Bioscience's Board of Directors. His extensive experience and deep expertise in the development of groundbreaking therapies for neurological and rare diseases make him an invaluable addition to our leadership team”.
Upon undertaking his new position, we sat down with Dr. Weiner to get his thoughts on Novoron Bioscience and how he feels he will contribute.
Q: What interested you in joining the Novoron team?
DW: I have had a long-standing interest in the development of highly novel approaches to the treatment of neurological and rare diseases. The team at Novoron are leveraging deep biological insights into a family of high value drug targets. Opportunities like this are few are far between, and my hope is that I can leverage my experience to increase the probability that Novoron succeeds in their drug development efforts.
Q: How do you see your role and the value that you bring to Novoron?
DW: My hope is that as an independent board member at Novoron, I can leverage my drug development and biotechnology corporate experience to provide valuable strategic advice and counsel. Specifically, I plan to focus on supporting the management team in their research and development decision making, and the company in its efforts to raise capital to advance our novel therapeutic drug candidates toward approval for the treatment of neurological disease.
Q: What are you most excited about for the future of the company?
DW: A few things. The company has significantly advanced our understanding of the structure and function of LRP1 in the setting of spinal cord injury and neurodegenerative diseases, enabling the development of targeted therapeutics for multiple diseases. In addition, the company has strong management and investor support, key factors for future success.
These sentiments were further echoed by Dr. Stiles, “Dave has contributed in a variety of positions to the success and growth of companies tackling complex problems in the neuro space and his proven track record of success aligns perfectly with Novoron’s mission to pioneer transformative treatments for patients suffering from neurological damage and disease”.
About Novoron
Based in San Diego, California, Novoron Bioscience is a private biotechnology company that is focused on the development of novel therapeutics for central nervous system disorders. For more information about Novoron visit https://novoron.com